Vax­cyte makes deal with Sutro Bio­phar­ma to take over man­u­fac­tur­ing of vac­cine com­po­nent

Vax­cyte will pay Sutro Bio­phar­ma as much as $157.5 mil­lion to take over the man­u­fac­tur­ing and fu­ture de­vel­op­ment of the cell-free ex­tract used for its vac­cine can­di­dates.

Un­der the agree­ment, Vax­cyte is pay­ing $22.5 mil­lion up­front for the op­tion to work with a con­tract man­u­fac­tur­er to make the cell-free ex­tract and to de­vel­op it fur­ther. If it ex­er­cis­es the op­tion, it will pay $75 mil­lion, plus as much as $60 mil­lion in ad­di­tion­al mile­stone pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER